JP2019501202A - Ｂ型肝炎を治療するための治療用組成物及び方法 - Google Patents

Ｂ型肝炎を治療するための治療用組成物及び方法 Download PDF

Info

Publication number
JP2019501202A
JP2019501202A JP2018535880A JP2018535880A JP2019501202A JP 2019501202 A JP2019501202 A JP 2019501202A JP 2018535880 A JP2018535880 A JP 2018535880A JP 2018535880 A JP2018535880 A JP 2018535880A JP 2019501202 A JP2019501202 A JP 2019501202A
Authority
JP
Japan
Prior art keywords
inhibitor
inhibitors
reverse transcriptase
capsid
cccdna formation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018535880A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501202A5 (https=
Inventor
アンドレア クコナティ，
アンドレア クコナティ，
エイミー シー．エイチ． リー，
エイミー シー．エイチ． リー，
コルネリス エー． レインブランド，
コルネリス エー． レインブランド，
マイケル ジェイ． ソフィア，
マイケル ジェイ． ソフィア，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arbutus Biopharma Corp
Original Assignee
Tekmira Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59274445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2019501202(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tekmira Pharmaceuticals Corp filed Critical Tekmira Pharmaceuticals Corp
Publication of JP2019501202A publication Critical patent/JP2019501202A/ja
Publication of JP2019501202A5 publication Critical patent/JP2019501202A5/ja
Priority to JP2022065611A priority Critical patent/JP2022087209A/ja
Priority to JP2024076451A priority patent/JP2024105468A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
JP2018535880A 2016-01-08 2017-01-06 Ｂ型肝炎を治療するための治療用組成物及び方法 Pending JP2019501202A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022065611A JP2022087209A (ja) 2016-01-08 2022-04-12 Ｂ型肝炎を治療するための治療用組成物及び方法
JP2024076451A JP2024105468A (ja) 2016-01-08 2024-05-09 Ｂ型肝炎を治療するための治療用組成物及び方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662276722P 2016-01-08 2016-01-08
US62/276,722 2016-01-08
US201662343514P 2016-05-31 2016-05-31
US62/343,514 2016-05-31
US201662345476P 2016-06-03 2016-06-03
US62/345,476 2016-06-03
US201662409180P 2016-10-17 2016-10-17
US62/409,180 2016-10-17
US201662420969P 2016-11-11 2016-11-11
US62/420,969 2016-11-11
PCT/US2017/012614 WO2017120527A2 (en) 2016-01-08 2017-01-06 Therapeutic compositions and methods for treating hepatitis b

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022065611A Division JP2022087209A (ja) 2016-01-08 2022-04-12 Ｂ型肝炎を治療するための治療用組成物及び方法

Publications (2)

Publication Number Publication Date
JP2019501202A true JP2019501202A (ja) 2019-01-17
JP2019501202A5 JP2019501202A5 (https=) 2020-02-20

Family

ID=59274445

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018535880A Pending JP2019501202A (ja) 2016-01-08 2017-01-06 Ｂ型肝炎を治療するための治療用組成物及び方法
JP2022065611A Pending JP2022087209A (ja) 2016-01-08 2022-04-12 Ｂ型肝炎を治療するための治療用組成物及び方法
JP2024076451A Pending JP2024105468A (ja) 2016-01-08 2024-05-09 Ｂ型肝炎を治療するための治療用組成物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022065611A Pending JP2022087209A (ja) 2016-01-08 2022-04-12 Ｂ型肝炎を治療するための治療用組成物及び方法
JP2024076451A Pending JP2024105468A (ja) 2016-01-08 2024-05-09 Ｂ型肝炎を治療するための治療用組成物及び方法

Country Status (16)

Country Link
US (2) US20190282604A1 (https=)
EP (1) EP3400008A4 (https=)
JP (3) JP2019501202A (https=)
KR (2) KR20180120675A (https=)
CN (1) CN110022895A (https=)
AU (3) AU2017205650A1 (https=)
BR (1) BR112018013928A2 (https=)
CA (1) CA3009996A1 (https=)
CL (2) CL2018001858A1 (https=)
CO (1) CO2018008249A2 (https=)
HK (1) HK1255835A1 (https=)
IL (2) IL295692A (https=)
PH (1) PH12018501455A1 (https=)
SG (2) SG10201912314QA (https=)
TW (4) TW201735950A (https=)
WO (1) WO2017120527A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023526346A (ja) * 2020-05-15 2023-06-21 福建▲広▼生中霖生物科技有限公司 三環式化合物を含む組み合わせ及びｈｂｖ治療薬物の製造におけるその使用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4512407A3 (en) 2018-07-13 2025-09-24 F. Hoffmann-La Roche AG Oligonucleotides for modulating rtel1 expression
US20200332297A1 (en) * 2019-04-18 2020-10-22 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
MA55720A (fr) * 2019-04-18 2022-02-23 Janssen Pharmaceuticals Inc Polythérapie pour le traitement d'une infection par le virus de l'hépatite b
CN114828852A (zh) * 2019-12-24 2022-07-29 豪夫迈·罗氏有限公司 用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合
JP2024537830A (ja) * 2021-10-08 2024-10-16 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド カプシドタンパク質阻害剤と逆転写酵素阻害剤とを含む医薬組合せ
CN117771361B (zh) * 2024-02-27 2024-06-07 天津中逸安健生物科技有限公司 一种聚肌苷酸-聚胞苷酸复合物的脂质纳米佐剂及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150174115A1 (en) * 2013-03-12 2015-06-25 Novira Therapeutics, Inc. Hepatitis b antiviral agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6809083B1 (en) * 1998-02-12 2004-10-26 Richard A. Mueller Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections
WO2001045712A1 (de) * 1999-12-22 2001-06-28 Bayer Aktiengesellschaft Arzneimittelkombinationen gegen virale erkrankungen
WO2004050613A2 (en) * 2002-12-02 2004-06-17 Gilead Sciences, Inc. 2-substituted-3-propenamide derivatives and methods of using the same
US20110218512A1 (en) * 2008-06-03 2011-09-08 Aethlon Medical, Inc. Enhanced antiviral therapy methods and devices
SG181633A1 (en) * 2009-12-31 2012-07-30 xiao-jian Zhou Compositions and methods for treating hepatitis b virus infection
WO2012024170A2 (en) * 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2013308045B2 (en) * 2012-08-30 2018-10-04 Replicor Inc. Methods for the treatment of hepatitis B and hepatitis D infections
CA2948580A1 (en) * 2014-05-09 2015-11-12 Adam Zlotnick Methods and compositions for treating hepatitis b virus infections
US10550084B2 (en) * 2017-12-04 2020-02-04 Arbutus Biopharma Corporation Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same
US10358447B2 (en) * 2017-12-04 2019-07-23 Arbutus Biopharma Corporation Substituted 2-N-hydroxy-1,3-dioxo-1,2,3,4-tetrahydronaphthyridines, and methods of making and using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150174115A1 (en) * 2013-03-12 2015-06-25 Novira Therapeutics, Inc. Hepatitis b antiviral agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. MED. CHEM., (2011), 54, [16], P.5660-5670, JPN6021004416, ISSN: 0004660549 *
J. MOL. RECOGNIT., (2006), 19, [6], P.542-548, JPN6021004414, ISSN: 0004660548 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023526346A (ja) * 2020-05-15 2023-06-21 福建▲広▼生中霖生物科技有限公司 三環式化合物を含む組み合わせ及びｈｂｖ治療薬物の製造におけるその使用
JP7706475B2 (ja) 2020-05-15 2025-07-11 福建▲広▼生中霖生物科技有限公司 三環式化合物を含む組み合わせ及びｈｂｖ治療薬物の製造におけるその使用
US12569500B2 (en) 2020-05-15 2026-03-10 Fujian Akeylink Biotechnology Co., Ltd. Combination comprising tricycle compound and use thereof in preparation of medicament for treating HBV

Also Published As

Publication number Publication date
TW202211912A (zh) 2022-04-01
TW202322791A (zh) 2023-06-16
TW202435851A (zh) 2024-09-16
BR112018013928A2 (en) 2018-12-11
JP2024105468A (ja) 2024-08-06
AU2017205650A1 (en) 2018-07-19
US20240050463A1 (en) 2024-02-15
KR20180120675A (ko) 2018-11-06
SG10201912314QA (en) 2020-02-27
CN110022895A (zh) 2019-07-16
TW201735950A (zh) 2017-10-16
CL2018001858A1 (es) 2018-11-23
PH12018501455A1 (en) 2019-03-18
WO2017120527A2 (en) 2017-07-13
EP3400008A4 (en) 2019-10-09
CA3009996A1 (en) 2017-07-13
HK1255835A1 (zh) 2019-08-30
EP3400008A2 (en) 2018-11-14
IL303754A (en) 2023-08-01
CL2023000892A1 (es) 2023-09-29
IL295692A (en) 2022-10-01
US20190282604A1 (en) 2019-09-19
WO2017120527A3 (en) 2017-08-31
AU2025217340A1 (en) 2025-11-06
SG11201805729SA (en) 2018-08-30
AU2022203814A1 (en) 2022-06-23
KR20250089561A (ko) 2025-06-18
CO2018008249A2 (es) 2018-08-21
JP2022087209A (ja) 2022-06-09

Similar Documents

Publication Publication Date Title
JP5766188B2 (ja) 固形腫瘍に治療剤を送達するための脂質製剤
JP5475753B2 (ja) 核酸送達用の脂質製剤
JP6275655B2 (ja) トリアルキルカチオン性脂質およびその使用方法
US11904052B2 (en) Methods for ameliorating infusion reactions
JP2022087209A (ja) Ｂ型肝炎を治療するための治療用組成物及び方法
EP3634431A1 (en) Therapeutic compositions and methods for treating hepatitis b
WO2016071857A1 (en) Compositions and methods for silencing ebola virus expression
WO2017019891A2 (en) Compositions and methods for silencing hepatitis b virus gene expression
JP2017536092A (ja) Ｂ型肝炎ウイルスの遺伝子発現をサイレンシングするための組成物及び方法
WO2018232330A1 (en) Therapeutic compositions and methods for treating hepatitis b
AU2013202932A1 (en) Novel lipid formulations for nucleic acid delivery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181120

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20181120

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20181121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210816

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211213